Global Antibiotic R&D Partnership (GARDP)
@gardp.bsky.social
Putting public health needs at the centre of antibiotic drug development to address the crisis of antimicrobial resistance (AMR).
https://gardp.org/this-is-big/
https://gardp.org/this-is-big/
Pinned
Announced in 2019, 5 BY 25 was an ambitious goal to tackle AMR. Launched today, the report shows how GARDP developed 5+ treatments focused on priority infections while strengthening antibiotic R&D, manufacturing and access.
🔗 Read the report: gardp.org/publications...
🔗 Read the report: gardp.org/publications...
Proud to participate in the #AMRKenya2026 in Mombasa. GARDP Africa Director Carol Ruffell joined a key panel on financing the AMR agenda and funding opportunities for LMICs.
👏Huge congrats to the Kenyan Ministry of Health, Kemri Wellcome Trust and partners for hosting such an important meeting.
👏Huge congrats to the Kenyan Ministry of Health, Kemri Wellcome Trust and partners for hosting such an important meeting.
January 23, 2026 at 8:34 AM
Proud to participate in the #AMRKenya2026 in Mombasa. GARDP Africa Director Carol Ruffell joined a key panel on financing the AMR agenda and funding opportunities for LMICs.
👏Huge congrats to the Kenyan Ministry of Health, Kemri Wellcome Trust and partners for hosting such an important meeting.
👏Huge congrats to the Kenyan Ministry of Health, Kemri Wellcome Trust and partners for hosting such an important meeting.
🆕GARDP signs MoU with Tamrisa to share its CMC & clinical expertise for the development of TMR010, a preclinical antibacterial targeting carbapenem-resistant Enterobacterales
The MoU also opens future collab pathways for more antibiotic developers to benefit from GARDP’s CMC & clinical expertise.
The MoU also opens future collab pathways for more antibiotic developers to benefit from GARDP’s CMC & clinical expertise.
January 22, 2026 at 6:37 AM
🆕GARDP signs MoU with Tamrisa to share its CMC & clinical expertise for the development of TMR010, a preclinical antibacterial targeting carbapenem-resistant Enterobacterales
The MoU also opens future collab pathways for more antibiotic developers to benefit from GARDP’s CMC & clinical expertise.
The MoU also opens future collab pathways for more antibiotic developers to benefit from GARDP’s CMC & clinical expertise.
🚀 ACC2026 is coming up soon
This free, global, online conference brings together leading minds and experts to explore what’s next for antimicrobial chemotherapy.
Co-organized by GARDP and BSAC
📅 4–5 Feb 2026 |🌍 Online
🔗 Register now: bit.ly/4pSEdt7
@bsacandjac.bsky.social @advance-id.bsky.social
This free, global, online conference brings together leading minds and experts to explore what’s next for antimicrobial chemotherapy.
Co-organized by GARDP and BSAC
📅 4–5 Feb 2026 |🌍 Online
🔗 Register now: bit.ly/4pSEdt7
@bsacandjac.bsky.social @advance-id.bsky.social
January 21, 2026 at 1:07 PM
🚀 ACC2026 is coming up soon
This free, global, online conference brings together leading minds and experts to explore what’s next for antimicrobial chemotherapy.
Co-organized by GARDP and BSAC
📅 4–5 Feb 2026 |🌍 Online
🔗 Register now: bit.ly/4pSEdt7
@bsacandjac.bsky.social @advance-id.bsky.social
This free, global, online conference brings together leading minds and experts to explore what’s next for antimicrobial chemotherapy.
Co-organized by GARDP and BSAC
📅 4–5 Feb 2026 |🌍 Online
🔗 Register now: bit.ly/4pSEdt7
@bsacandjac.bsky.social @advance-id.bsky.social
🎥 GARDP’s “5 BY 25” webinar recording is now available
Launched in 2019, 5 BY 25 aimed to develop 5 new antibiotic treatments by 2025. This session reflects its achievements, learnings & how that progress is shaping the next phase of antibiotic R&D & access.
▶️ https://bit.pulse.ly/vqea2b9uqk
Launched in 2019, 5 BY 25 aimed to develop 5 new antibiotic treatments by 2025. This session reflects its achievements, learnings & how that progress is shaping the next phase of antibiotic R&D & access.
▶️ https://bit.pulse.ly/vqea2b9uqk
January 20, 2026 at 5:59 PM
🎥 GARDP’s “5 BY 25” webinar recording is now available
Launched in 2019, 5 BY 25 aimed to develop 5 new antibiotic treatments by 2025. This session reflects its achievements, learnings & how that progress is shaping the next phase of antibiotic R&D & access.
▶️ https://bit.pulse.ly/vqea2b9uqk
Launched in 2019, 5 BY 25 aimed to develop 5 new antibiotic treatments by 2025. This session reflects its achievements, learnings & how that progress is shaping the next phase of antibiotic R&D & access.
▶️ https://bit.pulse.ly/vqea2b9uqk
💥A new GARDP programme has joined ENABLE-2 portfolio
The collab aims to develop a novel antibiotic class targeting critical survival pathways in high-priority drug-resistant Gram-negative bacteria under GARDP’s discovery and exploratory research efforts.
🔗 https://tinyurl.pulse.ly/c0wijeniga
The collab aims to develop a novel antibiotic class targeting critical survival pathways in high-priority drug-resistant Gram-negative bacteria under GARDP’s discovery and exploratory research efforts.
🔗 https://tinyurl.pulse.ly/c0wijeniga
January 20, 2026 at 9:21 AM
💥A new GARDP programme has joined ENABLE-2 portfolio
The collab aims to develop a novel antibiotic class targeting critical survival pathways in high-priority drug-resistant Gram-negative bacteria under GARDP’s discovery and exploratory research efforts.
🔗 https://tinyurl.pulse.ly/c0wijeniga
The collab aims to develop a novel antibiotic class targeting critical survival pathways in high-priority drug-resistant Gram-negative bacteria under GARDP’s discovery and exploratory research efforts.
🔗 https://tinyurl.pulse.ly/c0wijeniga
🌐 Registration remains open for ACC2026, an open-access, virtual conference jointly organized by GARDP & BSAC, with ADVANCE-ID & Mahidol Uni.
🌍 Free & fully online
📅 4–5 Feb 2026
🔗https://acc-conference.com/#registration
@bsacandjac.bsky.social I @advance-id.bsky.social
🌍 Free & fully online
📅 4–5 Feb 2026
🔗https://acc-conference.com/#registration
@bsacandjac.bsky.social I @advance-id.bsky.social
January 17, 2026 at 7:04 AM
🌐 Registration remains open for ACC2026, an open-access, virtual conference jointly organized by GARDP & BSAC, with ADVANCE-ID & Mahidol Uni.
🌍 Free & fully online
📅 4–5 Feb 2026
🔗https://acc-conference.com/#registration
@bsacandjac.bsky.social I @advance-id.bsky.social
🌍 Free & fully online
📅 4–5 Feb 2026
🔗https://acc-conference.com/#registration
@bsacandjac.bsky.social I @advance-id.bsky.social
📄New paper in @lancetmicrobe.bsky.social co-authored by GARDP & @globalamrhub.bsky.social analyzes global public & philanthropic investment in antibacterial R&D (2017–2023). It finds clinical funding steady while early-stage & pre-clinical investment declines.
🔗https://tinyurl.pulse.ly/fpn4wx1hel
🔗https://tinyurl.pulse.ly/fpn4wx1hel
tinyurl.pulse.ly
January 16, 2026 at 6:59 AM
📄New paper in @lancetmicrobe.bsky.social co-authored by GARDP & @globalamrhub.bsky.social analyzes global public & philanthropic investment in antibacterial R&D (2017–2023). It finds clinical funding steady while early-stage & pre-clinical investment declines.
🔗https://tinyurl.pulse.ly/fpn4wx1hel
🔗https://tinyurl.pulse.ly/fpn4wx1hel
🗣️ GARDP at parliamentary discussions on AMR
Peter Beyer took part in a parliamentary group on antimicrobial resistance organised by DNAMR. The discussion focused on how non-profit antibiotic R&D models can work in LMICs and the policy frameworks needed for access, pricing and technology sharing.
Peter Beyer took part in a parliamentary group on antimicrobial resistance organised by DNAMR. The discussion focused on how non-profit antibiotic R&D models can work in LMICs and the policy frameworks needed for access, pricing and technology sharing.
January 15, 2026 at 4:29 PM
🗣️ GARDP at parliamentary discussions on AMR
Peter Beyer took part in a parliamentary group on antimicrobial resistance organised by DNAMR. The discussion focused on how non-profit antibiotic R&D models can work in LMICs and the policy frameworks needed for access, pricing and technology sharing.
Peter Beyer took part in a parliamentary group on antimicrobial resistance organised by DNAMR. The discussion focused on how non-profit antibiotic R&D models can work in LMICs and the policy frameworks needed for access, pricing and technology sharing.
Reposted by Global Antibiotic R&D Partnership (GARDP)
📈 New NeoSep1 results!
Part 1 shows that fosfomycin and flomoxef are safe and well-tolerated in babies with sepsis. Part 2, designed by our experts, compares antibiotic combinations for treating neonatal sepsis.
@pentafoundation.bsky.social @gardp.bsky.social
Read more about it 👇
Part 1 shows that fosfomycin and flomoxef are safe and well-tolerated in babies with sepsis. Part 2, designed by our experts, compares antibiotic combinations for treating neonatal sepsis.
@pentafoundation.bsky.social @gardp.bsky.social
Read more about it 👇
Every year, sepsis claims hundreds of thousands of newborn lives, but new evidence offers hope. 👶
#NeoSep1 Part 1 shows off-patent antibiotics fosfomycin and flomoxef are safe and well tolerated in newborns with suspected #sepsis, including high-risk preterm infants. 💜
👇
#NeoSep1 Part 1 shows off-patent antibiotics fosfomycin and flomoxef are safe and well tolerated in newborns with suspected #sepsis, including high-risk preterm infants. 💜
👇
NeoSep1 Part 1 study shows promising antibiotic options for newborns with suspected sepsis - SNIP-AFRICA
A paper published in the journal Antimicrobial Agents and Chemotherapy (AAC) reports that off-patent antibiotics, fosfomycin and flomoxef, when used at standard doses, were safe in newborn babies with...
www.snip-africa.org
January 15, 2026 at 3:26 PM
📈 New NeoSep1 results!
Part 1 shows that fosfomycin and flomoxef are safe and well-tolerated in babies with sepsis. Part 2, designed by our experts, compares antibiotic combinations for treating neonatal sepsis.
@pentafoundation.bsky.social @gardp.bsky.social
Read more about it 👇
Part 1 shows that fosfomycin and flomoxef are safe and well-tolerated in babies with sepsis. Part 2, designed by our experts, compares antibiotic combinations for treating neonatal sepsis.
@pentafoundation.bsky.social @gardp.bsky.social
Read more about it 👇
Announced in 2019, 5 BY 25 was an ambitious goal to tackle AMR. Launched today, the report shows how GARDP developed 5+ treatments focused on priority infections while strengthening antibiotic R&D, manufacturing and access.
🔗 Read the report: gardp.org/publications...
🔗 Read the report: gardp.org/publications...
January 15, 2026 at 12:10 PM
Announced in 2019, 5 BY 25 was an ambitious goal to tackle AMR. Launched today, the report shows how GARDP developed 5+ treatments focused on priority infections while strengthening antibiotic R&D, manufacturing and access.
🔗 Read the report: gardp.org/publications...
🔗 Read the report: gardp.org/publications...
📢New partnership on gonorrhoea
GARDP and Debiopharm are partnering to advance Debio1453, a first-in-class antibiotic candidate for Neisseria gonorrhoeae, helping sustain the antibiotic pipeline as resistance grows.
🔗 Read the PR: https://gardp.pulse.ly/0ckjycxlvh
GARDP and Debiopharm are partnering to advance Debio1453, a first-in-class antibiotic candidate for Neisseria gonorrhoeae, helping sustain the antibiotic pipeline as resistance grows.
🔗 Read the PR: https://gardp.pulse.ly/0ckjycxlvh
January 13, 2026 at 1:09 PM
📢New partnership on gonorrhoea
GARDP and Debiopharm are partnering to advance Debio1453, a first-in-class antibiotic candidate for Neisseria gonorrhoeae, helping sustain the antibiotic pipeline as resistance grows.
🔗 Read the PR: https://gardp.pulse.ly/0ckjycxlvh
GARDP and Debiopharm are partnering to advance Debio1453, a first-in-class antibiotic candidate for Neisseria gonorrhoeae, helping sustain the antibiotic pipeline as resistance grows.
🔗 Read the PR: https://gardp.pulse.ly/0ckjycxlvh
⏰ Only a few days left to register for GARDP’s 5 BY 25 webinar.
We will discuss what the evidence from 5 BY 25 shows and how it is shaping the next phase of antibiotic R&D and access.
📅 15 Jan | 12:00–13:00 CET
🔗 https://gotowebinar.pulse.ly/sx58sweqro
#AMR #AntibioticResistance #GARDP
We will discuss what the evidence from 5 BY 25 shows and how it is shaping the next phase of antibiotic R&D and access.
📅 15 Jan | 12:00–13:00 CET
🔗 https://gotowebinar.pulse.ly/sx58sweqro
#AMR #AntibioticResistance #GARDP
January 11, 2026 at 6:59 AM
⏰ Only a few days left to register for GARDP’s 5 BY 25 webinar.
We will discuss what the evidence from 5 BY 25 shows and how it is shaping the next phase of antibiotic R&D and access.
📅 15 Jan | 12:00–13:00 CET
🔗 https://gotowebinar.pulse.ly/sx58sweqro
#AMR #AntibioticResistance #GARDP
We will discuss what the evidence from 5 BY 25 shows and how it is shaping the next phase of antibiotic R&D and access.
📅 15 Jan | 12:00–13:00 CET
🔗 https://gotowebinar.pulse.ly/sx58sweqro
#AMR #AntibioticResistance #GARDP
Reposted by Global Antibiotic R&D Partnership (GARDP)
The #NeoSep1 clinical trial is sponsored by @gardp.bsky.social in collaboration with @mrcctu.bsky.social, @citystgeorges.bsky.social and Penta.
The trial is also part of the #SNIP-AFRICA project, an African-European collaboration funded by @globalhealthedctp3.bsky.social & led by Penta.
The trial is also part of the #SNIP-AFRICA project, an African-European collaboration funded by @globalhealthedctp3.bsky.social & led by Penta.
Home - SNIP-AFRICA
SNIP-AFRICA is an African-European collaboration that aims to improve the way severe infections in newborns are treated. Using an innovative approach, SNIP-AFRICA will tackle questions around antibiot...
www.snip-africa.org
January 9, 2026 at 8:54 AM
The #NeoSep1 clinical trial is sponsored by @gardp.bsky.social in collaboration with @mrcctu.bsky.social, @citystgeorges.bsky.social and Penta.
The trial is also part of the #SNIP-AFRICA project, an African-European collaboration funded by @globalhealthedctp3.bsky.social & led by Penta.
The trial is also part of the #SNIP-AFRICA project, an African-European collaboration funded by @globalhealthedctp3.bsky.social & led by Penta.
Reposted by Global Antibiotic R&D Partnership (GARDP)
Every year, sepsis claims hundreds of thousands of newborn lives, but new evidence offers hope. 👶
#NeoSep1 Part 1 shows off-patent antibiotics fosfomycin and flomoxef are safe and well tolerated in newborns with suspected #sepsis, including high-risk preterm infants. 💜
👇
#NeoSep1 Part 1 shows off-patent antibiotics fosfomycin and flomoxef are safe and well tolerated in newborns with suspected #sepsis, including high-risk preterm infants. 💜
👇
NeoSep1 Part 1 study shows promising antibiotic options for newborns with suspected sepsis - SNIP-AFRICA
A paper published in the journal Antimicrobial Agents and Chemotherapy (AAC) reports that off-patent antibiotics, fosfomycin and flomoxef, when used at standard doses, were safe in newborn babies with...
www.snip-africa.org
January 9, 2026 at 8:51 AM
Good news for newborn health 👶
New findings from GARDP's #NeoSep1 trial show that off-patent antibiotics, fosfomycin & flomoxef, are safe in newborns with sepsis, supporting affordable treatment options where #AMR burden is highest
🔗 bit.ly/45oK3v1
@pentafoundation.bsky.social
@mrcctu.bsky.social
New findings from GARDP's #NeoSep1 trial show that off-patent antibiotics, fosfomycin & flomoxef, are safe in newborns with sepsis, supporting affordable treatment options where #AMR burden is highest
🔗 bit.ly/45oK3v1
@pentafoundation.bsky.social
@mrcctu.bsky.social
January 9, 2026 at 9:47 AM
Good news for newborn health 👶
New findings from GARDP's #NeoSep1 trial show that off-patent antibiotics, fosfomycin & flomoxef, are safe in newborns with sepsis, supporting affordable treatment options where #AMR burden is highest
🔗 bit.ly/45oK3v1
@pentafoundation.bsky.social
@mrcctu.bsky.social
New findings from GARDP's #NeoSep1 trial show that off-patent antibiotics, fosfomycin & flomoxef, are safe in newborns with sepsis, supporting affordable treatment options where #AMR burden is highest
🔗 bit.ly/45oK3v1
@pentafoundation.bsky.social
@mrcctu.bsky.social
Reposted by Global Antibiotic R&D Partnership (GARDP)
On 15 Jan 2026, @gardp.bsky.social will host a online webinar on “5 BY 25”, its 5-year initiative focused on advancing antimicrobial R&D and access.
Prof David Paterson will be part of the conversation.
⏰ 16:30-17:30 IST/13:00-14:00 SAST/ 19:00-20:00 GMT+8
Register here: ad-id.co/4pp1PFj
#AMR
Prof David Paterson will be part of the conversation.
⏰ 16:30-17:30 IST/13:00-14:00 SAST/ 19:00-20:00 GMT+8
Register here: ad-id.co/4pp1PFj
#AMR
January 9, 2026 at 9:11 AM
On 15 Jan 2026, @gardp.bsky.social will host a online webinar on “5 BY 25”, its 5-year initiative focused on advancing antimicrobial R&D and access.
Prof David Paterson will be part of the conversation.
⏰ 16:30-17:30 IST/13:00-14:00 SAST/ 19:00-20:00 GMT+8
Register here: ad-id.co/4pp1PFj
#AMR
Prof David Paterson will be part of the conversation.
⏰ 16:30-17:30 IST/13:00-14:00 SAST/ 19:00-20:00 GMT+8
Register here: ad-id.co/4pp1PFj
#AMR
Register now for the Global Health Institute’s webinar on the Local to Global Rise of Antimicrobial Resistance.
GARDP’s François Franceschi will join the panel alongside global health leaders.
📅 27 January 2026
⏰ 9–10am CST
🔗 Register: https://zoom.pulse.ly/dhjfoulfmd
#AMR #GlobalHealth #GARDP
GARDP’s François Franceschi will join the panel alongside global health leaders.
📅 27 January 2026
⏰ 9–10am CST
🔗 Register: https://zoom.pulse.ly/dhjfoulfmd
#AMR #GlobalHealth #GARDP
Welcome! You are invited to join a webinar: UW–Madison Global Health Institute Global Health Tuesday Webinar: Local to Global Rise in Antimicrobial Resistance. After registering, you will receive a confirmation email about joining the webinar.
The Global Health Institute’s January Global Health Tuesday Webinar is scheduled for Tuesday, January 27, 2026, from 9-10am CST. Laurel Legenza, Assistant Professor, School of Nursing, UW–Madison, moderates a timely conversation on Local to Global Rise in Antimicrobial Resistance.
Legenza will lead the discussion with panelists François Franceschi, Head of Asset Evaluation and Development and Serious Bacterial Infections Project Leader, Global Antibiotic Research & Development Partnership (GARDP); and Dr. Erta Kalanxhi, Director of Partnerships, One Health Trust.
zoom.pulse.ly
January 7, 2026 at 11:00 AM
Register now for the Global Health Institute’s webinar on the Local to Global Rise of Antimicrobial Resistance.
GARDP’s François Franceschi will join the panel alongside global health leaders.
📅 27 January 2026
⏰ 9–10am CST
🔗 Register: https://zoom.pulse.ly/dhjfoulfmd
#AMR #GlobalHealth #GARDP
GARDP’s François Franceschi will join the panel alongside global health leaders.
📅 27 January 2026
⏰ 9–10am CST
🔗 Register: https://zoom.pulse.ly/dhjfoulfmd
#AMR #GlobalHealth #GARDP
A great visit to Chennai, India to meet Orchid Pharma, GARDP’s manufacturing sublicensee for the Reserve antibiotic cefiderocol. Since 2022, GARDP has partnered with Shionogi and CHAI to expand access to this WHO Essential Medicine. Encouraging progress on API, finished dosage and ESHS standards.
January 7, 2026 at 7:21 AM
A great visit to Chennai, India to meet Orchid Pharma, GARDP’s manufacturing sublicensee for the Reserve antibiotic cefiderocol. Since 2022, GARDP has partnered with Shionogi and CHAI to expand access to this WHO Essential Medicine. Encouraging progress on API, finished dosage and ESHS standards.
Registrations are open for ACC2026, a free, 2-day online conference on the latest advances in antimicrobial research.
Organised by GARDP & BSAC, with collab partners ADVANCE-ID & Mahidol University.
📆 4–5 Feb 2026
🔗 https://bit.pulse.ly/qmgpewgvig
@bsacandjac.bsky.social I @advance-id.bsky.social
Organised by GARDP & BSAC, with collab partners ADVANCE-ID & Mahidol University.
📆 4–5 Feb 2026
🔗 https://bit.pulse.ly/qmgpewgvig
@bsacandjac.bsky.social I @advance-id.bsky.social
January 5, 2026 at 6:59 AM
Registrations are open for ACC2026, a free, 2-day online conference on the latest advances in antimicrobial research.
Organised by GARDP & BSAC, with collab partners ADVANCE-ID & Mahidol University.
📆 4–5 Feb 2026
🔗 https://bit.pulse.ly/qmgpewgvig
@bsacandjac.bsky.social I @advance-id.bsky.social
Organised by GARDP & BSAC, with collab partners ADVANCE-ID & Mahidol University.
📆 4–5 Feb 2026
🔗 https://bit.pulse.ly/qmgpewgvig
@bsacandjac.bsky.social I @advance-id.bsky.social
💻 Join GARDP’s webinar on the progress and lessons from 5 BY 25, our multi-year effort to advance new antibiotic treatments.
We will share key results shaping the next phase of antibiotic R&D and access.
📅 15 Jan | 12:00–13:00 CET
🔗 https://gotowebinar.pulse.ly/xzadk4tr7b
We will share key results shaping the next phase of antibiotic R&D and access.
📅 15 Jan | 12:00–13:00 CET
🔗 https://gotowebinar.pulse.ly/xzadk4tr7b
January 2, 2026 at 6:59 AM
💻 Join GARDP’s webinar on the progress and lessons from 5 BY 25, our multi-year effort to advance new antibiotic treatments.
We will share key results shaping the next phase of antibiotic R&D and access.
📅 15 Jan | 12:00–13:00 CET
🔗 https://gotowebinar.pulse.ly/xzadk4tr7b
We will share key results shaping the next phase of antibiotic R&D and access.
📅 15 Jan | 12:00–13:00 CET
🔗 https://gotowebinar.pulse.ly/xzadk4tr7b
2025 was a BIG year for GARDP 🎉
We delivered our first FDA-approved treatment, proving the power of a non-profit partnership model.
Excited for 2026, let’s keep tackling AMR together! 🚀
Happy New Year and a successful start to 2026! 🎆
We delivered our first FDA-approved treatment, proving the power of a non-profit partnership model.
Excited for 2026, let’s keep tackling AMR together! 🚀
Happy New Year and a successful start to 2026! 🎆
January 1, 2026 at 7:00 AM
2025 was a BIG year for GARDP 🎉
We delivered our first FDA-approved treatment, proving the power of a non-profit partnership model.
Excited for 2026, let’s keep tackling AMR together! 🚀
Happy New Year and a successful start to 2026! 🎆
We delivered our first FDA-approved treatment, proving the power of a non-profit partnership model.
Excited for 2026, let’s keep tackling AMR together! 🚀
Happy New Year and a successful start to 2026! 🎆
🚀 GARDP and BIRAC, India is partnering to strengthen antibiotic R&D and access.
From sharing hard-won lessons from current antibiotic development projects to advancing CMC capabilities and shared learning, this partnership aims to turn innovation into real-world impact against AMR.
From sharing hard-won lessons from current antibiotic development projects to advancing CMC capabilities and shared learning, this partnership aims to turn innovation into real-world impact against AMR.
December 31, 2025 at 5:59 AM
🚀 GARDP and BIRAC, India is partnering to strengthen antibiotic R&D and access.
From sharing hard-won lessons from current antibiotic development projects to advancing CMC capabilities and shared learning, this partnership aims to turn innovation into real-world impact against AMR.
From sharing hard-won lessons from current antibiotic development projects to advancing CMC capabilities and shared learning, this partnership aims to turn innovation into real-world impact against AMR.
The Guardian highlights GARDP’s NeoSep1 trial, evaluating combinations of older antibiotics across eight countries to improve treatment for neonatal sepsis.
The trial will enroll 3,000 babies to help identify safer, more effective options.
🔗 https://theguardian.pulse.ly/cklhxhmbli
@theguardian.com
The trial will enroll 3,000 babies to help identify safer, more effective options.
🔗 https://theguardian.pulse.ly/cklhxhmbli
@theguardian.com
Antibiotic resistance: how a pioneering trial is using old drugs to save babies from sepsis
The infection is responsible for 800,000 newborn deaths each year, but clinics in eight countries are working together to find new treatments
theguardian.pulse.ly
December 29, 2025 at 6:59 AM
The Guardian highlights GARDP’s NeoSep1 trial, evaluating combinations of older antibiotics across eight countries to improve treatment for neonatal sepsis.
The trial will enroll 3,000 babies to help identify safer, more effective options.
🔗 https://theguardian.pulse.ly/cklhxhmbli
@theguardian.com
The trial will enroll 3,000 babies to help identify safer, more effective options.
🔗 https://theguardian.pulse.ly/cklhxhmbli
@theguardian.com
A @thelancet.com study highlights access gap in treating drug-resistant infections in LMICs.
Only 6.9% people with carbapenem-resistant Gram-negative infections received an appropriate antibiotic.
AMR is not only about overuse. For many, it is about lack of access
🔗 https://bit.pulse.ly/ucoyrqhysu
Only 6.9% people with carbapenem-resistant Gram-negative infections received an appropriate antibiotic.
AMR is not only about overuse. For many, it is about lack of access
🔗 https://bit.pulse.ly/ucoyrqhysu
December 26, 2025 at 6:59 AM
A @thelancet.com study highlights access gap in treating drug-resistant infections in LMICs.
Only 6.9% people with carbapenem-resistant Gram-negative infections received an appropriate antibiotic.
AMR is not only about overuse. For many, it is about lack of access
🔗 https://bit.pulse.ly/ucoyrqhysu
Only 6.9% people with carbapenem-resistant Gram-negative infections received an appropriate antibiotic.
AMR is not only about overuse. For many, it is about lack of access
🔗 https://bit.pulse.ly/ucoyrqhysu
📚 The holiday slowdown is a chance to catch up on reading.
This year’s REVIVE Antimicrobial Viewpoints examine antibiotic discovery gaps, cross resistance & other approaches to slowing #AMR.
Our 2025 pieces are available, with three recent titles previewed below.
🔗 https://bit.pulse.ly/a7hvwmo04k
This year’s REVIVE Antimicrobial Viewpoints examine antibiotic discovery gaps, cross resistance & other approaches to slowing #AMR.
Our 2025 pieces are available, with three recent titles previewed below.
🔗 https://bit.pulse.ly/a7hvwmo04k
December 24, 2025 at 6:59 AM
📚 The holiday slowdown is a chance to catch up on reading.
This year’s REVIVE Antimicrobial Viewpoints examine antibiotic discovery gaps, cross resistance & other approaches to slowing #AMR.
Our 2025 pieces are available, with three recent titles previewed below.
🔗 https://bit.pulse.ly/a7hvwmo04k
This year’s REVIVE Antimicrobial Viewpoints examine antibiotic discovery gaps, cross resistance & other approaches to slowing #AMR.
Our 2025 pieces are available, with three recent titles previewed below.
🔗 https://bit.pulse.ly/a7hvwmo04k